Recent clinical findings highlight a significant breakthrough regarding HFpEF and MASLD survival rates through modern metabolic therapies. Metabolic dysfunction-associated steatotic liver disease (MASLD) frequently complicates heart failure (HF), leading to a poorer prognosis. However, new research demonstrates that sodium-glucose cotransporter 2 (SGLT2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists provide substantial survival benefits for these high-risk patients. These therapies address the metabolic derangements that often drive cardiovascular decline.

Clinical Impact on HFpEF and MASLD Survival

A large-scale retrospective study utilized deidentified electronic health record data from the TriNetX global research network to evaluate these associations. The researchers consistently linked MASLD to an increased risk of nonfatal cardiovascular events and all-cause mortality in patients with heart failure. Consequently, clinicians must prioritize metabolic health to improve long-term outcomes in this population. The study found that SGLT2 inhibitors were associated with a 21% reduction in all-cause mortality for those with HFpEF and MASLD. Notably, GLP-1 receptor agonists showed even more robust results, with a 39% reduction in mortality and a 32% reduction in heart failure hospitalizations.

Furthermore, these survival benefits remained consistent regardless of whether patients had concomitant diabetes mellitus. This finding suggests that the cardioprotective and hepatoprotective effects of these drugs extend beyond simple glycemic control. Therefore, patients with obesity and metabolic liver disease may benefit from these agents early in their treatment course. Additionally, the study emphasizes that MASLD serves as a critical marker for adverse outcomes, necessitating a multi-specialty approach involving cardiology, endocrinology, and hepatology. Thus, the integration of SGLT2 inhibitors and GLP-1 receptor agonists into standard care could transform the management of metabolic heart failure phenotypes.

Frequently Asked Questions

Are SGLT2 inhibitors effective for MASLD patients without diabetes?

Yes, the survival benefits for HFpEF and MASLD patients were consistent in both diabetic and non-diabetic populations, highlighting the broad metabolic utility of SGLT2 inhibitors.

How do GLP-1 receptor agonists impact heart failure hospitalizations?

GLP-1 receptor agonists were associated with a significant 32% lower risk of heart failure hospitalizations in patients diagnosed with both HFpEF and MASLD.

Why is MASLD significant in heart failure prognosis?

MASLD acts as a clinical marker for systemic metabolic dysfunction. Researchers have linked it to increased risks of nonfatal cardiovascular events and significantly higher mortality rates in heart failure patients.

Disclaimer: This content is for informational and educational purposes only and does not constitute medical advice. Always seek the advice of a physician or other qualified health provider with any questions regarding a medical condition. Refer to the latest local and national guidelines for clinical practice.

References

Tepetes NI et al. Improved Survival With Sodium-Glucose Cotransporter 2 Inhibitors and Glucagon-Like Peptide-1 Receptor Agonists in Patients With Heart Failure With Preserved Ejection Fraction and Metabolic Dysfunction-Associated Steatotic Liver Disease. Am J Ther. 2026 May 06. doi: 10.1097/MJT.0000000000002139. PMID: 42090713.

Ibrahim R, et al. SGLT2 inhibitors and cardiovascular outcomes in metabolic dysfunction-associated steatotic liver disease: A real-world retrospective cohort study. Am J Med. 2025 Jun 24. doi: 10.1016/j.amjmed.2025.06.012.

Mao X, et al. GLP-1 receptor agonist-SGLT-2 inhibitor combination and risk of major adverse liver and cardiovascular outcomes in adults with MASLD and type 2 diabetes. Hepatology. 2026 Apr 25. doi: 10.1097/HEP.0000000000001245.